Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Adlai NortyeANL +8.51% 14-Day RSI is 62.71 as of Jul. 22, 2026. The stock has 7 warning signs investors should review. Among 1,424 Biotechnology companies, Adlai Nortye ranks worse than 93.82% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-22), Adlai Nortye's 14-Day RSI is 62.71.
The industry rank for Adlai Nortye's 14-Day RSI or its related term are showing as below:
ANL's 14-Day RSI is ranked worse than 93.82% of 1424
companies
in the Biotechnology industry
Industry Median: 45.605
vs ANL: 62.71
Adlai Nortye (NAS:ANL) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Adlai Nortye 14-Day RSI Related Terms
ANL vs OMER, PRME, DNA: 14-Day RSI Comparison
For the Biotechnology subindustry, Adlai Nortye's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adlai Nortye 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adlai Nortye's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Adlai Nortye's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adlai Nortye (ANL) has a 14-Day RSI of 62.71 as of Jul. 22, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Adlai Nortye and its competitors. According to the industry distribution chart, Adlai Nortye ranks #1336 out of 1424 companies in the Biotechnology industry, placing it in the top 93.8%.
Is Adlai Nortye's 14-Day RSI too high?
Adlai Nortye's current 14-Day RSI is 62.71. The Biotechnology industry median 14-Day RSI is 45.61. Adlai Nortye's value of 62.71 is 37.5% above this industry median. Based on the distribution chart, Adlai Nortye ranks #1336 out of 1424 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Adlai Nortye's 14-Day RSI compare to OMER and PRME?
According to the Biotechnology industry distribution chart, Adlai Nortye ranks #1336 out of 1424 companies for 14-Day RSI. This places Adlai Nortye in the lower half of its industry. The industry median 14-Day RSI is 45.61. Adlai Nortye's value of 62.71 is 37.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 45.61, based on 1,424 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Adlai Nortye's current 14-Day RSI of 62.71 is 37.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Adlai Nortye and its competitors. For the Biotechnology industry, the median 14-Day RSI is 45.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adlai Nortye's current 14-Day RSI is 62.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adlai Nortye stock overvalued right now?
Adlai Nortye (ANL) has a current 14-Day RSI of 62.71. The current 14-Day RSI is 62.71 and 37.5% above the Biotechnology industry median of 45.61. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Adlai Nortye (ANL), the current 14-Day RSI is 62.71 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANL has been successfully added to your 
